An update on the immune landscape in lung and head a

Citation Report

#	ARTICLE	IF	CITATIONS
1	Is There a Role for Immunotherapy in Prostate Cancer?. Cells, 2020, 9, 2051.	1.8	65
2	Recent updates on Sintilimab in solid tumor immunotherapy. Biomarker Research, 2020, 8, 69.	2.8	26
3	Industry and MASCC—an opportunity not to be missed. Supportive Care in Cancer, 2021, 29, 559-561.	1.0	1
4	<i>YKT6</i> , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration. OncoImmunology, 2021, 10, 1938890.	2.1	46
5	Long non-coding RNA ZNF674-AS1 regulates miR-23a/E-cadherin axis to suppress the migration and invasion of non-small cell lung cancer cells. Translational Cancer Research, 2021, 10, 4116-4124.	0.4	4
6	CCR4, CCR8, and P2RY14 as Prognostic Factors in Head and Neck Squamous Cell Carcinoma Are Involved in the Remodeling of the Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 618187.	1.3	10
7	The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis. Frontiers in Oncology, 2020, 10, 626932.	1.3	11
8	Molecular Characteristics, Prognostic Value, and Immune Characteristics of m6A Regulators Identified in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 629718.	1.3	9
9	The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. Molecules, 2021, 26, 1392.	1.7	21
10	Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model. Frontiers in Oncology, 2021, 11, 632364.	1.3	44
11	Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non–Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis. Clinical Lung Cancer, 2021, 22, e889-e900.	1.1	9
12	Cytoplasmic Localization Isoform of Cyclin Y Enhanced the Metastatic Ability of Lung Cancer via Regulating Tropomyosin 4. Frontiers in Cell and Developmental Biology, 2021, 9, 684819.	1.8	3
13	Prognostic values and clinical relationship of TYK2 in laryngeal squamous cell cancer. Medicine (United States), 2021, 100, e27062.	0.4	3
14	Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 685047.	1.3	2
15	Whole-Exome Sequencing on Circulating Tumor Cells Explores Platinum-Drug Resistance Mutations in Advanced Non-small Cell Lung Cancer. Frontiers in Genetics, 2021, 12, 722078.	1.1	10
16	Low expression of CIP4 in predicting worse overall survival: A potential biomarker for laryngeal cancer. PLoS ONE, 2021, 16, e0253545.	1.1	0
17	Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2021, 12, 757047.	2.2	8
18	First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis. Cancer Medicine, 2021, 10, 9139.	1.3	4

#	ARTICLE	IF	CITATIONS
19	A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer. Lung Cancer, 2022, 165, 18-27.	0.9	12
20	Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma. Journal of Personalized Medicine, 2022, 12, 12.	1.1	5
21	Identification and Validation of Immune Infiltration Phenotypes in Laryngeal Squamous Cell Carcinoma by Integrative Multi-Omics Analysis. Frontiers in Immunology, 2022, 13, 843467.	2.2	8
22	Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinomaï¼š A Retrospective Study. Frontiers in Oncology, 2022, 12, 820302.	1.3	12
23	The Application of Nanotechnology in Immunotherapy based Combinations for Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, 53-65.	0.8	1
24	Melatonin inhibits EMT and PDâ€‘L1 expression through the ERK1/2/FOSL1 pathway and regulates antiâ€‘tumor immunity in HNSCC. Cancer Science, 2022, 113, 2232-2245.	1.7	16
25	An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma. Frontiers in Oncology, 2022, 12, 800315.	1.3	2
26	Long non-coding RNA human leucocyte antigen complex group-18 HCG18 (HCG18) promoted cell proliferation and migration in head and neck squamous cell carcinoma through cyclin D1-WNT pathway. Bioengineered, 2022, 13, 9425-9434.	1.4	6
27	2-Deoxy-2-[18F] Fluoro-d-Glucose PET/Computed Tomography. PET Clinics, 2022, 17, 307-317.	1.5	0
28	Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. BMC Cancer, 2021, 21, 1322.	1.1	7
29	Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review. Translational Cancer Research, 2021, 10, 5406-5429.	0.4	4
30	Downregulated Expression of RIPOR3 Correlated with Immune Infiltrates Predicts Poor Prognosis in Oral Tongue Cancer. Medical Science Monitor, 2022, 28, e935055.	0.5	2
31	Shooting at Moving and Hidden Targetsâ€”Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas. Cancers, 2021, 13, 6219.	1.7	14
32	AQP9 and ZAP70 as immune-related prognostic biomarkers suppress proliferation, migration and invasion of laryngeal cancer cells. BMC Cancer, 2022, 22, 465.	1.1	2
33	Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study. BMC Pulmonary Medicine, 2022, 22, 166.	0.8	10
34	Prognostic value of CD247 in patients with head and neck squamous cell carcinoma: bioinformatic analysis of TCGA database. Annals of Translational Medicine, 2022, 10, 923-923.	0.7	3
35	Identification of Significant Secreted or Membrane-Located Proteins in Laryngeal Squamous Cell Carcinoma. Journal of Immunology Research, 2022, 2022, 1-11.	0.9	6
36	Construction of a prognostic immune-related lncRNA model and identification of the immune microenvironment in middle- or advanced-stage lung squamous carcinoma patients. Heliyon, 2022, 8, e09521.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Reporting quality of clinical practice guidelines on head and neck cancer: a systematic review. Translational Cancer Research, 2022, 11, 1795-1805.	0.4	1
38	Current Insights in Nutrition Assessment and Intervention for Malnutrition or Muscle Loss in People with Lung Cancer: A Narrative Review. Advances in Nutrition, 2022, 13, 2420-2432.	2.9	5
39	LINC01116 Promotes Migration and Invasion of Oral Squamous Cell Carcinoma by Acting as a Competed Endogenous RNA in Regulation of MMP1 Expression. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-10.	0.7	5
40	PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. Molecular Pharmaceutics, 2022, 19, 3471-3483.	2.3	4
41	Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents. BMC Cancer, 2022, 22, .	1.1	0
42	Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites. Frontiers in Immunology, 0, 13, .	2.2	5
43	PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications. Biomedicine and Pharmacotherapy, 2022, 153, 113458.	2.5	5
44	Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB. Disease Markers, 2022, 2022, 1-25.	0.6	7
45	Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event. Frontiers in Immunology, 0, 13, .	2.2	2
46	BIRC5 Modulates PD-L1 Expression and Immune Infiltration in Lung Adenocarcinoma. Journal of Cancer, 2022, 13, 3140-3150.	1.2	12
47	Integrative Analysis of N6-Methyladenosine-Related Enhancer RNAs Identifies Distinct Prognosis and Tumor Immune Micro-Environment Patterns in Head and Neck Squamous Cell Carcinoma. Cancers, 2022, 14, 4657.	1.7	2
48	Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 4253-4267.	1.2	3
49	Identification and Validation of Three-Gene Signature in Lung Squamous Cell Carcinoma by Integrated Transcriptome and Methylation Analysis. Journal of Oncology, 2022, 2022, 1-13.	0.6	2
50	Non-coding RNA-mediated high expression of SFXN3 as a prognostic biomarker associated with paclitaxel resistance and immunosuppressive microenvironment in head and neck cancer. Frontiers in Immunology, 0, 13, .	2.2	2
51	A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma. Frontiers in Immunology, 0, 13, .	2.2	15
52	Targeting the DNA Damage Response Machinery for Lung Cancer Treatment. Pharmaceuticals, 2022, 15, 1475.	1.7	6
53	Association between psoriasis and lung cancer: two-sample Mendelian randomization analyses. BMC Pulmonary Medicine, 2023, 23, .	0.8	4
54	Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for â€œcoldâ€• tumor immunotherapy. Acta Biomaterialia, 2023, 159, 338-352.	4.1	3

#	ARTICLE	IF	CITATIONS
55	Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma. Frontiers in Immunology, 0, 14, .	2.2	1
56	Adjuvant PD-1 antibody in recurrent, previously irradiated oral cavity cancer treated with salvage surgery. Clinical and Translational Radiation Oncology, 2023, 40, 100623.	0.9	0
57	Competitive endogenous RNA-mediated upregulation of PLOD2 expression correlates with poor prognosis and tumor immune infiltration of head and neck squamous cell carcinoma. , 2023, 6, 100026.		0
58	A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysisâ€Targeting Chimeras Enhanced Immunotherapy. Advanced Materials, 2023, 35, .	11.1	11
59	DKK1 affects survival of patients with head and neck squamous cell carcinoma by inducing resistance to radiotherapy and immunotherapy. Radiotherapy and Oncology, 2023, 181, 109485.	0.3	3
60	Natural peptides for immunological regulation in cancer therapy: Mechanism, facts and perspectives. Biomedicine and Pharmacotherapy, 2023, 159, 114257.	2.5	14
61	Noninvasive evaluation of PD-L1 expression in non-small cell lung cancer by immunoPET imaging using an acylating agentâ€"modified antibody fragment. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1585-1596.	3.3	2
63	The clinical safety and efficacy of targeted PD-L1 therapy with durvalumab in solid tumors. Current Drug Targets, 2023, 24, .	1.0	1